盐酸多柔比星(Doxorubicin Hydrochloride) - 药物靶点：Top II_在研适应症：艾滋病相关性卡波西肉瘤，卡波西肉瘤，骨癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DOX@3D-MPs、doxorubicin、Doxorubicin hydrochloride (JP17/USP)

+ [32]

靶点

Top II

作用方式

抑制剂

作用机制

Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [10]

在研适应症

艾滋病相关性卡波西肉瘤卡波西肉瘤骨癌+ [57]

非在研适应症

腺样囊性癌腺肉瘤晚期乳腺癌+ [34]

原研机构

Pfizer Inc.

在研机构

Baxter Holdings Ltd. (Japan)山德士有限公司Hoffmann-La Roche, Inc.

+ [13]

非在研机构

Ortho Biotech, Inc.

SanofiJanssen Research & Development LLC

+ [24]

权益机构

Ipsen SA

Baxter International, Inc.

Chong Kun Dang Pharmaceutical Corp.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1974-08-07),

急性淋巴细胞白血病急性髓性白血病乳腺癌+ [9]

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C27H30ClNO11

InChIKeyMWWSFMDVAYGXBV-RUELKSSGSA-N

CAS号25316-40-9

关联

1,685

项与盐酸多柔比星相关的临床试验

NCT07076186

/ Not yet recruiting临床2期IIT

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in Uterine Leiomyosarcoma

The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.

开始日期2025-12-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT07049848

/ Not yet recruiting临床2期IIT

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

The goal of this clinical research study is to look at the effectiveness of giving a combination of chemotherapy, immunotherapy, radiation therapy, and surgery to treat soft tissue sarcomas that can be removed by surgery. Researchers want to find out if this treatment combination can extend the time it takes for the disease to relapse (come back after treatment). The safety of this treatment combination will also be studied.

开始日期2025-12-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT07078604

/ Not yet recruiting临床2期IIT

A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients With Metastatic Triple-Negative Breast Cancer

This phase II trial studies how well a cancer vaccine called STEMVAC works in combination with chemotherapy in treating patients with PD-L1 negative, triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that are expressed on breast cancer stem cells, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. The allowable combination chemotherapy includes: (1) Paclitaxel is in a class of chemotherapy medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. (2) Docetaxel is in a class of chemotherapy medications called taxanes. It stops tumor cells from growing and dividing and may kill them. (3) Cisplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. (4) Carboplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. (5) Doxorubicin is in a class of chemotherapy medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. (6) Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. (7) Eribulin is in a class of chemotherapy medications called microtubule dynamics inhibitors. It works by stopping the growth and spread of tumor cells. Giving STEMVAC in combination with chemotherapy may be an effective treatment for PD-L1 negative metastatic triple-negative breast cancer.

开始日期2025-12-01

申办/合作机构

University of Washington

100 项与盐酸多柔比星相关的临床结果

登录后查看更多信息

100 项与盐酸多柔比星相关的转化医学

登录后查看更多信息

100 项与盐酸多柔比星相关的专利（医药）

登录后查看更多信息

111,654

项与盐酸多柔比星相关的文献（医药）

2026-01-01·BIOMATERIALS

Modulating tumor acidity with hydroxyethyl starch-based nanoparticles by targeting CA9 to eliminate cancer stem cells and overcome immunosuppression

Article

作者: Yang, Xiangliang ; Hua, Ao ; Li, Zifu ; Zhang, Zhijie ; Deng, Qingyuan ; Yang, Tian ; Zhao, Qingfu ; Wang, Qiang

The acidic microenvironment in solid tumors, primarily driven by Warburg effect, promotes tumor progression, immune evasion, and resistance to therapy. Cancer stem cells (CSCs), a critical subset within tumor tissues, exacerbate this acidity through overexpression of pH-regulating proteins such as carbonic anhydrase IX (CA9), which plays a pivotal role in maintaining pH homeostasis, contributes to immune suppression, and sustains CSC stemness and proliferation. In this study, we designed CA9 inhibitor (CAi) coupled hydroxyethyl starch-based nanoparticles (CHHD-Cu NPs) that integrate doxorubicin (DOX) mediated chemotherapy with copper ions (Cu²⁺) mediated chemodynamic therapy to target and eliminate CA9-expressing CSCs. Upon administration, CHHD-Cu NPs bind to CA9 and disrupt pH regulation, thereby lowering intracellular pH and raising extracellular pH. This pH modulation enhances intracellular releases of DOX and Cu²⁺ and alleviates extracellular acidity to boost effector T cells infiltration and activity. Our rationally designed CHHD-Cu NPs eliminate CSCs in two ways: firstly, by robust intracellular DOX- and copper-induced cytotoxicity, and secondly, via pH modulation-mediated activation of anti-tumor immunity. Our strategy offers novel approaches for treatment of immunosuppressive solid tumors.

2026-01-01·BIOMATERIALS

Gold-embedded yolk-shell mesoporous organosilica nanocomposite for microwave-enhanced targeted chemotherapy and immune modulation in hepatocellular carcinoma

Article

作者: Wang, Shouju ; Sun, Hanyao ; Liu, Sheng ; Zhang, Jie ; Tian, Wei ; Li, Yang ; Xu, Jiaqi ; Luo, Yafei ; Luo, Xi ; Li, Na ; Tang, Jiajia ; Shi, Haibin ; Lu, Shangyu ; Yuan, Chen ; Xu, Ziqing

Microwave ablation (MWA), an innovative therapy for hepatocellular carcinoma (HCC), faces challenges of limited thermal effects and a tumor immunosuppressive microenvironment. Addressing these, we developed an advanced Au@PMO@DOX-Lac nanocomposite, aimed at enhancing the microwave thermal effect, while simultaneously facilitating targeted chemotherapy and immunomodulation. This nanocomposite, incorporating gold-embedded yolk-shell mesoporous organosilica nanoparticles, amplifies microwave thermal effects from two aspects: molecular hotspots created at the gold-silica interface and the confinement effect within its hollow nanostructure. These enhancements facilitate more effective tumor ablation with reduced microwave power requirements and shorter treatment durations. Additionally, surface modification with lactobionic acid and loading with doxorubicin allow the nanocomposite to perform precise, targeted synergistic chemotherapy. After ablation, the nanocomposite increased cytotoxic T cells and reduced regulatory T cells, while shifting macrophages from the immunosuppressive M2 to the anti-tumor M1 phenotype, significantly enhancing localized and systemic anti-tumor immune responses. Overall, this multifunctional nanocomposite not only overcomes the thermal limitations of MWA but also addresses the tumor's immunosuppressive environment, providing a promising approach for treating HCC and potentially other cancers with similar therapeutic challenges.

2026-01-01·TALANTA

Robust removal of thallium(I) from water with nano-MnO2 implanted zwitterionic porous hydrogel

Article

作者: Wu, Hongjie ; Jia, Xiaoyu ; Gong, Dirong

The uncontrolled disposal of Tl(I) waste comes at a significant economic and environmental cost because of the acute toxicity and high mobility. To resolve the aggregation problem for most reported MnO₂ based adsorbent materials which significantly affected the adsorption efficiency, porous zwitterionic ammonium propyl sulfonate (zw) polyacrylamide hydrogel (PAAm) has been fabricated to disperse nano-MnO₂ as a support. The developed nano-MnO₂@PAAm-zw exhibited a specific surface area of 5.06 m²/g and a pore diameter of 23.8 nm. particularly amenable to removal of Tl(I) for environmental remediation. The factors, including adsorbent MnO₂ incorporation, feeding amount, adsorption time, pH of the solution, Tl(I) initial concentration and existence of competing cations that governing the adsorption performances were fully elucidated. The maximal removal capacity Q_e reaches up to 336.5 mg (Tl) g^-1(MnO₂) with 99.92 % elimination efficiency and a low residue of 4.5 μg L^-1. The materials exhibit an astonishing robustness against nature matrix and high concentration of cations with adsorption capacity being 928.6-41.43 times larger than various competing counterparts for lab-made and mineral samples, representing the state-of-the-art level of adsorbents. The adsorbent can be regenerated at least five times retaining 86.0 % of original efficiency. A novel concerted mechanistic pathway of retention mainly associated with re-dox reaction is possible. These features offer great potentials for selective and deep elimination of total thallium in water samples.

1,090

项与盐酸多柔比星相关的新闻（医药）

2025-07-24

·药时代

科济炸场后，实体瘤CAR-T东风再起！

全文共2874字，共0图预计阅读时间：8分钟继科济药业公布其在研的Claudin18.2自体CAR-T疗法——舒瑞基奥仑赛的新药上市申请已获NMPA正式受理的喜讯后，实体瘤CAR-T再度引发市场关注。当地时间2025年7月23日，一家初创的实体瘤CAR-T公司——Dispatch Bio（Dispatch）宣布获得2.16亿美元A轮融资。从融资规模来看，2.16亿美元的A轮融资在如今的大环境下是鲜少的。就国内最近情况来看，A轮融资金额数值普遍在数千万元。比较高的，比如柏全生物、凯米生物也只到2亿元左右。再从Biospace提到的国外初创公司（比如Draig Therapeutics和Granite Bio）情况来看，A轮融资金额也普遍徘徊在1亿美元左右。放在CGT领域，这2.16亿美元更是难得。以同类的实体瘤CAR-T海外公司的融资情况进行类比。2024年9月，实体瘤CAR-T明星企业——Arsenal Biosciences的C轮融资也不过3.25 亿美元。此前，Arsenal的A轮融资仅8500万美元。值得探讨的是，在资本寒冬背景下，此次大额融资叠加全球首款实体瘤CAR-T疗法即将上市的预期，是否预示着该赛道拐点已经到来？关于Dispatch Bio分析认为，投资人看上Dispatch主要有两大原因：1）创始团队“咖位”大；2）技术平台有优势。Dispatch于2022年由美国知名VC Arch Venture Partners和帕克癌症免疫治疗研究所（PICI）合作成立。此本轮融资的投资者除Arch和PICI外，还有BMS、宾夕法尼亚大学、斯坦福大学和亚历山大风险投资公司。Dispatch的核心技术平台——Flare技术源自“CAR-T之父”Carl June、斯坦福大学Chris Garcia教授、加州大学旧金山分校的Kole Roybal教授，以及斯隆-凯特琳癌症中心免疫肿瘤学新任主席Andy Minn实验室的突破性技术的融合而建立。基于Flare技术的CAR-T疗法与我们所熟知的CAR-T疗法的主要区别在于：不依赖肿瘤天然表达的有限抗原。传统CAR-T疗法起作用的核心逻辑是，让经改造的T细胞去识别并清除带有特定靶标的肿瘤细胞。目前，全球共获批上市12款CAR-T疗法，其中8款靶向CD 19，另4款靶向BCMA。这两个靶点的共同特点是，均在特定的血液系统恶性肿瘤表面高表达，但在正常组织中几乎不表达。这反映了传统CAR-T设计理念的一个问题，即对靶点本身具有较高要求。这在很大程度上限制了CAR-T疗法在肿瘤领域的”开疆扩土”。相比之下，Flare技术则是先通过基因工程改造的病毒给肿瘤细胞安装上一个特定的“信号弹”——抗原Flare，之后让经改造的T细胞去识别带有“Flare”标识的肿瘤细胞，进而达到清除目的。此外，Dispatch信息显示，抗原Flare的载体病毒还能递送炎症细胞因子和趋化因子，这可以帮助摧毁肿瘤周围的环境防御。基于这种“没有靶标就创造靶标”，“靶标难识别、易脱靶就人工创造容易识别靶标”的思路，经Flare技术加持的下一代CAR-T疗法或许能使CAR-T赛道突破现有瓶颈。Flare：实体瘤治愈的利器？Dispatch成立的宗旨是希望有朝一日所有癌症患者都能得到治愈。这是一个宏伟的愿景。癌症，根据生物学特性和发生部位，可被笼统的分为实体瘤和血液肿瘤。最早出现的肿瘤治疗手段的是手术治疗，就是简单的肿块/瘤子切除。然后是放疗，即放射治疗，主要是通过大量辐射杀死癌细胞。全球首个抗肿瘤药物的上市要追溯到20世纪40年代。1949年，氮芥获FDA批准上市，成为历史上第一个有记载的抗肿瘤化疗药物。后随生物技术发展，包括阿霉素、顺铂、紫杉醇、吉西他滨等在内的化疗药物陆续获批上市。科研界在上世纪后半叶取得的一系列突破促生了肿瘤靶向治疗药物。后来CTLA-4、PD-1等免疫检查点的陆续发现又为肿瘤患者群体带来了突破性的免疫检查点抑制剂。现如今的肿瘤治疗方式呈现手术、放化疗、靶向治疗、免疫治疗、细胞基因疗法等多种治疗方式单药/联合治疗的多元格局。其中，CAR-T细胞疗法凭借其突破性疗效，已成为肿瘤免疫治疗领域最受瞩目的技术方向之一。在一些科普文章中，CAR-T疗法常与“肿瘤治愈”相关联。这倒不是什么夸张说法，因为目前确实有真实治愈案例——白血病患者艾米莉。艾米莉于7岁时接受CAR-T治疗，到2025年已经无癌生存13年。CAR-T疗法治愈肿瘤的核心在于其独特的“精准强化+免疫突破”双作用模式。通过人工嵌入特定”CAR"基因片段，改造后的T细胞一方面可直接识别肿瘤表面抗原（如CD19），另一方面体外扩增的CAR-T细胞回输后数量可达10^9级别，形成“免疫风暴”，并在患者体内长期存活。这种独特优势是ADC和免疫检查点抑制剂所不能的，是深层的机制差异。科济药业的舒瑞基奥仑赛目前显示出的疗效离治愈仍有差距。据舒瑞基奥仑赛II期确证性CT041-ST-01研究结果，相较标准治疗方案，舒瑞基奥仑赛可实现mPFS显著延长，至3.25个月。mOS也显示出获益趋势，至7.92个月。不过据科济早期报道，在一项研究中，接受局部治疗和另一款实体瘤CAR-T疗法联合治疗后，两名患者在长期随访（从2015年到2023年）中均保持了无瘤状态。从机制上讲，如果Flare技术平台能同时解决传统CAR-T抗原依赖及肿瘤微环境防御两大难题，的确让实体瘤的治愈愿景离实现又近了一步。参考资料：1.https://www.biopharmadive.com/news/disptach-bio-universal-cancer-immunotherapy-solid-tumors/753743/ 2.https://www.zhihu.com/tardis/zm/art/3362446693.人类肿瘤药物治疗史上的三次革命：从化疗药物到靶向药物、免疫治疗药物——中国医保肿瘤用药发展史-中国医疗保险杂志社4.https://www.hangyan.co/charts/35931998528146000855.各公司官网6.其他公开资料图片来源：即梦AI股价暴涨400%！IBD领域迎来新秀2025-07-23多款药物惨遭FDA拒批！居然因为...2025-07-23下一代靶向TMPRSS6的siRNA疗法寻找合作伙伴 | 药时代BD项目2025-07-22版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多精彩！

2025-07-23

·学术经纬

5年生存率不足10%：挽救致命脑癌患者，这些创新策略有望突破血脑屏障

编者按：作为一种常见的高度恶性脑胶质瘤，胶质母细胞瘤（Glioblastoma, GBM）的发病机制复杂，当下的治疗仍然面临巨大挑战。临床统计数据显示，GBM患者的中位生存期仅为12-15个月，5年生存率不足10%。近些年来，科学家正致力于研究能助力药物突破血脑屏障的全新策略，为GBM治疗注入新的力量。药明康德也一直在支持GBM等脑肿瘤疗法的开发，致力于通过独特的一体化、端到端CRDMO模式，助力合作伙伴的新药加速问世。本文将分享GBM疗法在解决血脑屏障递送难题方面的部分前沿进展。胶质母细胞瘤（GBM）是成人群体中发病率最高、恶性程度最强的原发性脑肿瘤，被世界卫生组织（WHO）定义为IV级胶质瘤。该肿瘤以侵袭性生长和高复发率为特征，患者确诊后的中位生存期仅约12-15个月，5年生存率更是低于10%。当前GBM的标准治疗方案包括手术切除、放射治疗和替莫唑胺（TMZ）化疗。虽然这些治疗手段能短暂改善患者预后，但疗效往往较为有限。TMZ的治疗效果常因肿瘤细胞产生耐药性而大打折扣，且部分携带特定基因特征的患者几乎对TMZ无应答。为此，科学家正在积极探索各类创新疗法以延长患者生存期。图片来源：123RF在GBM的疗法探索中，血脑屏障的存在成为一道必须要突破的屏障。作为血液与脑组织间的选择性过滤器，这一生理屏障能有效阻挡病原体和有害物质入脑；但与此同时，其致密结构也阻断了绝大多数药物进入脑组织发挥作用，导致GBM治疗面临巨大挑战。纳米载体突破血脑屏障近年来，开发能高效穿透血脑屏障的递送策略已成为GBM研究的重点方向。其中一个方向是纳米载体，这项技术将药物或生物活性分子包裹在纳米结构中，既能防止药物降解，又能增强其稳定性，从而绕过血脑屏障的阻碍。纳米载体入脑后，科学家可采用多种方式触发药物释放。例如，热敏脂质体在达到特定温度时可以释放药物，研究者利用这一特性，通过红外线照射实现了药物的局部控释。今年Journal of Pharmaceutical Sciences杂志的一项研究就展示了热敏脂质体搭载TMZ类药物在GBM模型中的测试结果。图片来源：123RF研究者通过鼻内给药方式向GBM小鼠递送了该纳米颗粒。这些纳米颗粒可以被鼻黏膜有效吸收，并且展现出高度安全性。通过脑部红外照射，研究者检查到了纳米载体内部药物的大量释放。经过热敏脂质体治疗的小鼠，大脑中GBM肿瘤细胞凋亡显著增加，中位生存期相较于化疗对照组也得到提升。此外，声控纳米载体也展现出了治疗潜力，比如Biomaterials Advances期刊的一项研究展示了一种可以被超声波调控的脂质体颗粒。该载体搭配了阿霉素，可以在超声波诱导后显著提升阿霉素的释放和累积，增强对GBM的局部杀伤。除此之外，超声波干预本身也可以通过微气泡形式介导血脑屏障的开放，提升药物的渗透性。新型小分子登场除了开发纳米载体，挖掘出能突破血脑屏障的小分子药物也是科学家重点关注的另一个方向。《自然》杂志的一项研究就发现了一种可击杀胶质母细胞瘤的毒素分子，其能通过抑制胶质母细胞瘤DNA和RNA的生成来促进细胞应激和死亡。在细胞测试中，这种小分子既能有效杀伤胶质母细胞瘤，又不会影响正常的胚胎成纤维细胞生存。在胶质母细胞瘤小鼠模型中，该分子可以随着血液穿透血脑屏障，随后在大脑的外周组织中逐渐累积。接受治疗的小鼠，肿瘤进展发生减缓，小鼠生存率显著提升，展现出广阔的应用前景。图片来源：123RF最近，另一项研究介绍了一种能够穿透血脑屏障并靶向微管发挥作用的新型小分子药物。微管是细胞骨架的重要组成部分，参与细胞分裂、形态维持和物质运输等功能。微管靶向药物通过干扰微管动力学来抑制肿瘤细胞增殖，是癌症治疗中的重要药物类别。但现有的微管靶向药物因为分子量大难以穿透血脑屏障，无法帮助到包括GBM在内的脑癌患者。而这种小分子因其极低的分子量和极性表面积，可以顺利穿过血脑屏障。动物实验显示，只需口服给药就能使脑组织药物浓度显著增加，远超体外抑制GBM肿瘤生长所需的浓度，并且这一过程无需额外激活途径。同时，该分子也展现出了良好的安全性与有效性，对多种GBM细胞系展现出抗肿瘤活性。在接近临床特征的GBM小鼠模型中，该分子能够抑制肿瘤发展，延长小鼠的生存期。论文信息显示，药明康德为该研究提供了赋能。CRDMO平台赋能GBM新药研发作为医药创新的赋能者，药明康德多年以来通过其一体化、端到端的CRDMO平台，为包括GBM在内的广泛疾病新药研发提供全方位的支持，助力全球合作伙伴加速突破性疗法面世，早日造福病患。在突破血脑屏障挑战领域，公开信息显示，药明康德DMPK自2009年起开始进行CNS相关研究，拥有超过15年的临床前CNS药物研发经验，建立了针对CNS药物体外血脑屏障通透性评价的特色且准确性较高的“漏斗”模型。通过完善的体外、体内测试平台，药明康德DMPK能够快速、准确、高效地对CNS药物进行全方位药代动力学相关评价，筛选出具有良好的脑通透性及稳定性的CNS候选药物。根据早前公开信息，该平台已完成包括常规小分子、治疗性蛋白、寡核苷酸等新分子实体类型项目百余项，成功助力全球客户多个CNS药物进入临床阶段。随着更多能突破血脑屏障的创新策略涌现，科学家有望推动更多GBM疗法诞生，进一步改善GBM患者的生存预后。相信在不远的将来，这一难治性疾病将迎来全新希望。欢迎转发到朋友圈，谢绝转载到其他平台。如有开设白名单需求，请在“学术经纬”公众号主页回复“转载”获取转载须知。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。更多推荐点个“在看”再走吧~

放射疗法

2025-07-23

·Firstwordpharma

J&J’s Imbruvica scores EU nod for front-line MCL as alternative to stem cell transplant

Johnson & Johnson on Wednesday said the European Commission (EC) greenlit an additional indication for its BTK inhibitor Imbruvica (ibrutinib), this time as an alternative front-line treatment option to autologous stem cell transplant (ASCT) for mantle cell lymphoma (MCL).Specifically, the approval covers ibrutinib in combination with rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), alternating with rituximab, dexamethasone, high-dose cytarabine and cisplatin or oxaliplatin (R‑DHAP/R‑DHAOx) without Imbruvica, followed by Imbruvica maintenance for previously untreated ASCT-eligible patients.Today's approval for frontline use offers patients…improved survival outcomes from the outset of treatment,” said Ester in 't Groen, EMEA therapeutic area head of haematology at Johnson & Johnson Innovative Medicine. The label expansion — which comes close on the heels of a positive stance adopted by the EU drug advisory panel last month — is backed by findings from the Phase III TRIANGLE study, which showed Imbruvica plus chemoimmunotherapy (CIT) — with or without ASCT — significantly improved failure-free survival (77% vs 68%) and overall survival (88% vs 78%) at 54 months versus ASCT plus CIT.Ibrutinib, first authorised in the EU in 2014, holds approvals in MCL, chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia across various lines of treatment, as monotherapy and in combination with chemotherapy and targeted therapies. Earlier this year, the EC cleared AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab as the first and only BTK inhibitor for first-line use in patients with MCL ineligible for ASCT.

上市批准临床3期临床结果免疫疗法细胞疗法

100 项与盐酸多柔比星相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01275	盐酸多柔比星	L01DB01	DB00997

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
艾滋病相关性卡波西肉瘤	日本	Baxter Holdings Ltd. (Japan)	2007-01-04
卡波西肉瘤	日本	Mochida Pharmaceutical Co., Ltd.	2007-01-04
骨癌	日本	山德士有限公司	2005-02-14
骨组织肿瘤	日本	山德士有限公司	2005-02-14
儿童恶性实体瘤	日本	山德士有限公司	2005-02-14
子宫内膜癌	日本	山德士有限公司	2005-02-14
尤文肉瘤	日本	山德士有限公司	2005-02-14
肝母细胞瘤	日本	山德士有限公司	2005-02-14
多发性骨髓瘤	日本	山德士有限公司	2005-02-14
视网膜母细胞瘤	日本	山德士有限公司	2005-02-14
横纹肌肉瘤	日本	山德士有限公司	2005-02-14
软组织肿瘤	日本	山德士有限公司	2005-02-14
尿路上皮癌	日本	山德士有限公司	2004-01-03
肺癌	中国	辉瑞制药（无锡）有限公司	2001-01-01
胃癌	美国	Pfizer Inc.	1987-12-23
卵巢癌	美国	Pfizer Inc.	1987-12-23
膀胱癌	日本	山德士有限公司	1979-05-22
急性淋巴细胞白血病	美国	Pfizer Inc.	1974-08-07
急性髓性白血病	美国	Pfizer Inc.	1974-08-07
乳腺癌	美国	Pfizer Inc.	1974-08-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	申请上市	中国	NATCO Pharma Ltd.	2022-01-30
肿瘤	申请上市	中国	Dr. Reddy's Laboratories Ltd.	2022-01-30
复发性多发性骨髓瘤	临床3期	美国	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	阿根廷	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	澳大利亚	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	奥地利	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	比利时	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	加拿大	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	捷克	Janssen Research & Development LLC	2004-12-01
复发性多发性骨髓瘤	临床3期	法国	Janssen Research & Development LLC	2004-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00878254 (CTgov)	临床2期	套细胞淋巴瘤	25	G-CSF+Mesna+Etoposide+Cyclophosphamide+Leucovorin+Doxorubicin+ifosfamide+Methotrexate+Rituximab+Vincristine+Cytarabine	獵衊築遞淵製製醖積簾(艱廠壓膚鏇壓選壓淵夢) = 築願糧觸範夢鏇衊觸齋範選齋選糧衊觸醖鹹簾 (齋蓋鏇積鏇積衊衊製窪, 廠製艱鹽製鹽繭鏇糧觸 ~ 衊積艱夢衊淵膚廠壓膚) 更多	-	2025-07-23
NCT03930680 (PHOENIX1, CTgov)	临床1期	心脏衰竭 \| 乳腺癌	25	Dexrazoxane (Dexrazoxane 100mg/m2)	窪壓齋鹹餘獵淵觸遞衊 = 願衊鹹繭顧餘壓鏇選鬱壓網淵積簾願淵鏇衊獵 (廠窪選艱簾糧觸鑰窪夢, 簾鹽鏇築製鏇繭餘鏇糧 ~ 顧構網鏇齋糧願鹹鏇衊) 更多	-	2025-06-12
				Dexrazoxane (Dexrazoxane 200mg/m2)	窪壓齋鹹餘獵淵觸遞衊 = 蓋蓋積遞構鬱鏇鬱齋鏇壓網淵積簾願淵鏇衊獵 (廠窪選艱簾糧觸鑰窪夢, 鹽餘選鑰廠醖製簾膚鏇 ~ 淵選餘壓齋鏇蓋膚餘醖) 更多
NCT00476190 (CTgov)	临床2期	成人急性淋巴细胞白血病	112	Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks)	淵鹹繭夢廠鏇觸範餘蓋 = 構醖蓋願鹹築窪鏇選鹹廠製壓鹽蓋觸鑰顧觸獵 (願衊網夢積衊築壓獵廠, 餘顧觸夢膚顧鏇壓積範 ~ 鏇蓋鏇獵蓋獵鬱構襯範) 更多	-	2025-06-12
				Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks)	淵鹹繭夢廠鏇觸範餘蓋 = 簾築壓膚蓋觸遞淵鹹蓋廠製壓鹽蓋觸鑰顧觸獵 (願衊網夢積衊築壓獵廠, 艱膚願壓壓範夢糧餘鹽 ~ 願廠廠積醖憲獵衊窪積) 更多
ASCO2025	N/A	乳腺癌辅助 Her2 neu negative	-	Doxorubicin/cyclophosphamide combined with paclitaxel (ACT)	鬱築選齋簾憲鏇窪網襯(鬱製願糧構積範簾築衊) = 齋網夢選積願夢獵簾獵衊淵艱憲積膚齋鏇觸網 (願餘獵餘衊糧願餘廠壓 ) 更多	不佳	2025-05-30
				Docetaxel/cyclophosphamide (TC)	鬱築選齋簾憲鏇窪網襯(鬱製願糧構積範簾築衊) = 願衊鹹簾窪鬱積憲夢衊衊淵艱憲積膚齋鏇觸網 (願餘獵餘衊糧願餘廠壓 ) 更多
ASCO2025	N/A	平滑肌肉瘤维持	20	Doxorubicin plus dacarbazine	窪積衊壓鑰積鏇憲製範(範願衊範繭觸觸鹽簾蓋) = 鏇夢築膚顧夢觸鏇鑰膚鏇襯壓醖範夢艱糧鏇網 (鏇齋願鑰淵製顧糧艱鹹 )	积极	2025-05-30
ASCO2025	N/A	子宫平滑肌肉瘤辅助	76	Doxorubicin-based chemotherapy	願憲餘餘廠鑰構蓋壓窪(衊衊顧憲糧衊鏇積壓繭) = Treatment with D was associated with improved PFS for metastatic ULMS compared to treatment with GT 繭鏇網顧餘鏇齋膚範積 (蓋廠廠願齋艱遞鑰選衊 )	积极	2025-05-30
				Gemcitabine/docetaxel
NCT04224337 (KCSG LU-19-24, ASCO2025)	临床2期	肺肉瘤样癌 PD-L1 positive	20	Durvalumab + Doxorubicin + Ifosfamide	蓋膚襯淵構淵艱網範壓(蓋顧齋積壓遞廠鏇醖獵) = 鬱衊積繭構繭遞憲蓋繭醖齋壓獵壓醖積憲鏇簾 (淵製網鹽衊衊鏇顧醖鹽, 17.7 ~ 55.8) 更多	积极	2025-05-30
ASCO2025	N/A	毒性	125	Pegylated liposomal doxorubicin (PLD) 20 mg/m2	範製製繭鹹憲襯憲願鬱(淵壓艱廠壓築醖蓋淵選) = Cardiac toxicity occurred in 3 patients 鏇製繭繭衊膚網鬱鹹製 (選簾網餘選廠製廠鬱範 ) 更多	-	2025-05-30
				Pegylated liposomal doxorubicin (PLD) 40 mg/m2
EHA2025 人工标引	N/A	弥漫性大B细胞淋巴瘤一线	16	dr-Pola-R-CHP	廠鏇築鏇構選簾膚鹹觸(蓋衊衊淵願構繭願簾艱) = 範鹽範範憲蓋襯淵範夢簾鏇窪觸鏇糧餘繭夢鹽 (範鹹製顧壓範網憲衊齋, 34 ~ 80) 更多	积极	2025-05-14
15-MDA-LNH-2023 (EHA2025) 人工标引	临床阶段不明	弥漫性大B细胞淋巴瘤一线	38	Polatuzumab-R-CHP	鬱夢襯鏇簾憲鑰網衊範(鬱蓋壓醖鬱積廠憲壓網) = 構願鬱窪範壓構廠鏇構糧襯觸壓繭窪鑰餘廠壓 (衊鹹蓋襯製鏇窪襯鑰夢 ) 更多	积极	2025-05-14